354 related articles for article (PubMed ID: 33528794)
1. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin.
Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D
Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794
[TBL] [Abstract][Full Text] [Related]
2. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
Veve MP; Wagner JL
Pharmacotherapy; 2018 Sep; 38(9):935-946. PubMed ID: 30019769
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Lefamulin: If Not Now, When?
Mercuro NJ; Veve MP
Curr Infect Dis Rep; 2020; 22(9):25. PubMed ID: 32834786
[TBL] [Abstract][Full Text] [Related]
4. Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin.
Paukner S; Goldberg L; Alexander E; Das AF; Heinrich S; Patel P; Moran GJ; Sandrock C; File TM; Vidal JE; Waites KB; Gelone SP; Schranz J
J Glob Antimicrob Resist; 2022 Jun; 29():434-443. PubMed ID: 34788694
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
[TBL] [Abstract][Full Text] [Related]
6. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA
Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830
[TBL] [Abstract][Full Text] [Related]
7. 7-Year (2015-21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms.
Paukner S; Mendes RE; Arends SJR; Gassner G; Gelone SP; Sader HS
J Antimicrob Chemother; 2024 Feb; 79(2):360-369. PubMed ID: 38113528
[TBL] [Abstract][Full Text] [Related]
8. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
[TBL] [Abstract][Full Text] [Related]
9. Lefamulin: The First Systemic Pleuromutilin Antibiotic.
Chahine EB; Sucher AJ
Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
[TBL] [Abstract][Full Text] [Related]
11.
Wu S; Zheng Y; Guo Y; Yin D; Zhu D; Hu F
Front Microbiol; 2020; 11():578824. PubMed ID: 33042095
[TBL] [Abstract][Full Text] [Related]
12. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline.
Dillon C; Guarascio AJ; Covvey JR
Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017
[TBL] [Abstract][Full Text] [Related]
13. Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials.
Paukner S; Mariano D; Das AF; Moran GJ; Sandrock C; Waites KB; File TM
Antibiotics (Basel); 2021 Dec; 10(12):. PubMed ID: 34943700
[TBL] [Abstract][Full Text] [Related]
14. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of lefamulin: A first-in-class semisynthetic pleuromutilin antibiotic.
Covvey JR; Guarascio AJ
J Intern Med; 2022 Jan; 291(1):51-63. PubMed ID: 34425035
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.
McCarthy MW
Clin Pharmacokinet; 2021 Nov; 60(11):1387-1394. PubMed ID: 34254252
[TBL] [Abstract][Full Text] [Related]
17. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
Watkins RR; File TM
Clin Infect Dis; 2020 Dec; 71(10):2757-2762. PubMed ID: 32221520
[TBL] [Abstract][Full Text] [Related]
18. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
[TBL] [Abstract][Full Text] [Related]
19. Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens.
Grossman TH; Fyfe C; O'Brien W; Hackel M; Minyard MB; Waites KB; Dubois J; Murphy TM; Slee AM; Weiss WJ; Sutcliffe JA
mSphere; 2017; 2(1):. PubMed ID: 28251179
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).
Paukner S; Gelone SP; Arends SJR; Flamm RK; Sader HS
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
